Advertisement
Canada markets open in 4 hours 25 minutes

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7310
    -0.0011 (-0.15%)
     

  • CRUDE OIL

    78.72
    +0.24 (+0.31%)
     

  • Bitcoin CAD

    87,850.36
    -1,352.41 (-1.52%)
     

  • CMC Crypto 200

    1,333.14
    -31.98 (-2.34%)
     

  • GOLD FUTURES

    2,323.70
    -7.50 (-0.32%)
     

  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ futures

    18,192.25
    -3.25 (-0.02%)
     

  • VOLATILITY

    13.53
    +0.04 (+0.30%)
     

  • FTSE

    8,303.41
    +89.92 (+1.09%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6790
    -0.0002 (-0.03%)
     

SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 1, 2021 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - October 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.

Class Period: December 27, 2018 and August 5, 2021
Lead Plaintiff Deadline: November 1, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SPPI:
https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=20576&from=5

Spectrum Pharmaceuticals, Inc. NEWS - SPPI NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Spectrum you have until November 1, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Spectrum securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SPPI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100360